Tag Archives: NASDAQ:GNOM

Eli Lilly (LLY) Releases Amyvid in US Markets

Posted on June 5, 2012 by Thomas Vedder

Eli Lilly and Company (NYSE:LLY) lately declared the launch of Amyvid (florbetapir F 18 Injection) its radioactive diagnostic agent, in few US markets. The firm reported that Amyvid is presented in imaging centers at markets in the neighborhood of 16 …

Posted in Healthcare, Latest Headlines | Tagged Abbott, arena, Complete Genomics, Dendreon, Eli Lilly, GlaxoSmithKline, IsoRay, LLY, NASDAQ:ARNA, NASDAQ:DNDN, NASDAQ:GNOM, NASDAQ:ZLCS, NYSE:ABT, NYSE:GSK, NYSE:LLY, NYSE:PFE, NYSEAMEX:ISR, Pfizer, Zalicus | Comments Off

Vertex Pharmaceutical Revises Cystic-Fibrosis Results – VRTX, BMY, MRK, PFE, THC, BSX, GNOM, AMRN, DNDN

Posted on May 29, 2012 by Geoff Noir

Vertex Pharmaceutical Inc. (NASDAQ:VRTX) revised the provisional outcomes of a new clinical experiment of cystic-fibrosis patients that had surpassed anticipations and increased optimism that the drug therapy experimented could have smash hit sales capabilities.

Vertex shares plunged almost 15% to …

Posted in Healthcare, Latest Headlines | Tagged Amarin, Boston Scientific, Bristol-Myers Squibb, Complete Genomics, Dendreon, Merck, NASDAQ:AMRN, NASDAQ:DNDN, NASDAQ:GNOM, NASDAQ:VRTX, NYSE:BMY, NYSE:BSX, NYSE:MRK, NYSE:PFE, NYSE:THC, Pfizer, Tenet, Vertex Pharmaceuticals, VRTX | Comments Off

Big time losers and the reasons why (ALNY, GNOM, YGE)

Posted on February 14, 2012 by Josie Middleton

In this report: Alnylam Pharmaceuticals (NASDAQ:ALNY), Complete Genomics (NASDAQ:GNOM) and Yingli Green Energy Holding Company (NYSE:YGE).

Alnylam Pharmaceuticals (NASDAQ:ALNY) shares have sunk 11.3 percent today after the company announced that it was planning a public offering of 7 million common …

Posted in Latest Headlines, Reports | Tagged ALNY, Alnylam Pharmaceuticals, Complete Genomics, GNOM, NASDAQ:ALNY, NASDAQ:GNOM, NYSE:YGE, YGE, Yingli Green Energy Holding Company | Comments Off

Monday’s top and bottom stock report

Posted on February 13, 2012 by Geoff Noir

Heres a look at the Top 10 most active gainers and decliners in 5 different U.S. exchanges.

NASDAQ

Complete Genomics (NASDAQ:GNOM) had over 20 million shares trade through its market today after the company announced that it had won a …

Posted in Latest Headlines, Reports | Tagged AMEX, AMEX:NEP, AMEX:QPSA, APCX, Apptech, Baron Capital Enterprise, BCAP, Chelsea Therapeutics International, China North East Petroleum, CHTP, Complete Genomics, Dex One Company, DEXO, Genta, GNOM, GTA, Imaging Diagnostics, IMDS, NASDAQ, NASDAQ:CHTP, NASDAQ:GNOM, National Bank of Greece, NBG, NEP, NYSE, NYSE:DEXO, NYSE:NBG, OTC:GNTA, OTC:IMDS, OTCBB, PINK:APCX, PINK:BCAP, pinksheets, QPSA, Quepasa Corp. | Comments Off

What the fuss NuVasive, Complete Genomics and Total System Services?

Posted on January 25, 2012 by Martin Timble

In this report: Complete Genomics (NASDAQ:GNOM), NuVasive (NASDAQ:NUVA) and Total Systems Services (NYSE:TSS).

Complete Genomics (NASDAQ:GNOM) shares soared to more than 20 percent higher today after it was announced that its competitor Illumina Inc. had become the target of a …

Posted in Latest Headlines, Reports | Tagged Complete Genomics, GNOM, NASDAQ:GNOM, NASDAQ:NUVA, NUVA, NuVasive, NYSE:TSS, Total Systems Services, TSS | Comments Off

Big time losers and the reasons why (TIF, GNOM, LIZ)

Posted on January 10, 2012 by Martin Timble

In this report: Tiffany & Co. (NYSE:TIF), Complete Genomics (NASDAQ:GNOM) and Liz Claiborne (NYSE:LIZ).

Tiffany & Co. (NYSE:TIF) shares have dropped by more than 10 percent today after the company announced that its sales growth slowed as shoppers in the …

Posted in Latest Headlines, Reports | Tagged company, Complete Genomics, downgraded, earnings, firm, fiscal, GNOM, growth, guidance, LIZ, Liz Claiborne, luxury, NASDAQ, NASDAQ:GNOM, NYSE, NYSE:LIZ, NYSE:TIF, Oppenheimer, outlook, rating, retailer, sales, shares, shoppers, stock, TIF, Tiffany & Co | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.